Stifel Financial
CAPR icon

Stifel Financial’s Capricor Therapeutics CAPR Stock Holding History

Stifel Financial’s Portfolio CAPR Stock Details CAPR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$288K Buy
11,956
+1,819
+18% +$55.2K ﹤0.01% 3312
2026
Q1 		$308K Buy
+10,137
New +$270K ﹤0.01% 3167

Other funds holding CAPR

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
TCM
Tang Capital Management San Diego, California $2.2B AUM 156.35% 1-Year Est. Return
SCM
Suvretta Capital Management New York $5.47B AUM 131.34% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
BCM
Boxer Capital Management San Diego, California $1.33B AUM 864.5% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Stifel Financial's CAPR Position: Q2 2026 in Review

Stifel Financial increased its Capricor Therapeutics (CAPR) stake by 18% in Q2 2026, buying an estimated $55.2K and bringing the position to 11,956 shares worth $288K. The position accounts for ﹤0.01% of the portfolio, ranked #3312.

Stifel Financial first reported a position in CAPR in Q1 2026 and has held it in 2 quarters since. The position peaked at $308K in Q1 2026. 170 funds tracked by Wall St. Rank hold CAPR as of Q2 2026.

  • Stifel Financial held 11,956 shares of Capricor Therapeutics worth $288K as of Q2 2026.
  • Stifel Financial bought 1,819 Capricor Therapeutics shares in Q2 2026, an estimated $55.2K.
  • Capricor Therapeutics made up ﹤0.01% of Stifel Financial's portfolio in Q2 2026, its #3312 holding.
  • Stifel Financial first reported a position in Capricor Therapeutics in Q1 2026 and has held it in 2 quarters since.
  • Stifel Financial's Capricor Therapeutics position peaked at $308K in Q1 2026.
  • 170 funds tracked by Wall St. Rank held Capricor Therapeutics as of Q2 2026.

Based on Stifel Financial's 13F filing for Q2 2026, filed 12 Aug 2026.